Omalizumab biosimilar (Mabtech)

奥马佐单抗生物类似药 (Mabtech)

Report date: 2026/03/10 20:00:16

Base Information

Drug NameOmalizumab biosimilar (Mabtech)
Drug Alias Name奥玛利珠单抗生物仿制药 (Mabtech)Omalizumab alpha奥马珠单抗生物仿制药 (Mabtech)奥马佐单抗生物仿制药 (Mabtech)奥马珠单抗α +[11] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionImmunoglobulin E inhibitorsImmunosuppressants
TargetsImmunoglobulin E
Therapy Area/IndicationsAllergic asthmaChronic UrticariaAsthma
Global Approved IndicationsAsthma
Approved Indications in ChinaAsthma
Original Approved Country/TerritoryMainland China
Original Approved Date2023/05/19
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Zhangjiang Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTaizhou Mabtech Pharmaceutical Co Ltd
Inactive CompaniesShanghai Biomabs Pharmaceuticals Co LtdTaizhou Maibo Taike Biotechnology Co LtdShanghai Zhangjiang Biotechnology Co Ltd
Active IndicationsChronic UrticariaAsthma
Inactive IndicationsAllergic asthma

Other Information

ATC CodeR03DX05
Related LinksN/A